Skip to main content
CELL BIOTECH CO ., LTD logo

CELL BIOTECH CO ., LTD — Investor Relations & Filings

Ticker · 049960 ISIN · KR7049960008 KO Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2022-03-15 AGM Information
Country KR South Korea
Listing KO 049960

About CELL BIOTECH CO ., LTD

https://www.cellbiotech.com/

CELL BIOTECH CO., LTD. is a biotechnology company specializing in the research, development, and manufacturing of probiotic solutions. With over three decades of experience, the company leverages its proprietary, worldwide-patented dual-coating technology, which is designed to ensure a higher survival rate for probiotic strains as they pass through the gastrointestinal tract. The company develops and utilizes its own GRAS (Generally Recognized as Safe) certified strains for its products. Its business encompasses the production of finished consumer products, such as the DUOLAC brand, and providing customized OEM/ODM services for the pharmaceutical and food supplement sectors.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Cell Biotech. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities and financial statements (balance sheet, income statement, etc.) for the 27th fiscal year. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the AGM and vote on agenda items, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It includes details on the meeting date, agenda items, and proxy solicitation procedures. While it contains financial statements, these are provided as supporting information for the shareholders' voting decisions, not as a standalone financial report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2022-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Report of Reason for Holding a General Meeting of Shareholders on a Concentrated Date'. It explains why the company scheduled its AGM on a date that coincides with many other companies' meetings. Since this is a specific regulatory disclosure regarding meeting logistics and does not fit into the categories of AGM presentations, proxy statements, or voting results, it is best classified as a general regulatory filing.
2022-03-15 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Cell Biotech. It outlines the date, location, agenda items (financial statements, director/auditor appointments, and business purpose changes), and voting procedures. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2022-03-02 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities regarding the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a corporate action related to share buybacks, which falls under the category of 'Transaction in Own Shares'.
2022-02-18 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Cell Biotech) regarding a significant change in financial results (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). This is a standard disclosure requirement in the Korean stock market (KRX) for preliminary earnings updates. Since it provides key financial highlights and performance drivers rather than a full annual report or a simple announcement of a report's availability, it falls under the Earnings Release (ER) category. FY 2021
2022-02-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.